Safety and efficacy of DB-1303 in patients with advanced/metastatic solid tumors: A multicenter, open-label, first-in-human, phase 1/2a study

被引：0
|
作者：
Moore, Kathleen N.
Sabanathan, Dhanusha
Du, Yiqun
Duan, Huaxin
Li, Xiumin
Wang, Feng
Marathe, Omkar
Yang, Hua
Makker, Vicky
Growdon, Whitfield
Coward, Jim
Zhao, Peng
Liu, Liming
Shi, Rong
Liu, Shengxue
Gu, Wei
Qiu, Yang
Zhu, Zhongyuan
Zhang, Jian
Hamilton, Erika P.
机构：
[1] Univ Oklahoma, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Macquarie Univ, Canc Inst, Sydney, Australia
[3] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China
[4] Hunan Prov Peoples Hosp, Changsha, Peoples R China
[5] Linyi Canc Hosp, Shandong, Peoples R China
[6] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
[7] Inst Oncol, Lakewood, CA USA
[8] Hebei Univ, Affiliated Hosp, Baoding, Hebei, Peoples R China
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Weill Cornell Med Coll, New York, NY USA
[11] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[12] ICON Canc Ctr, Brisbane, Australia
[13] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[14] Dual Biol, Philadelphia, PA USA
[15] Dual Biol, Princeton, NJ USA
[16] Dual Biol, Shanghai, Peoples R China
[17] Dual Biol, Basking Ridge, NJ USA
[18] Fudan Univ, Shanghai Canc Ctr, Phase 1 Clin Trial Ctr, Shanghai, Peoples R China
[19] Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai, Peoples R China
[20] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3023
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors
    Hamilton, Erika
    Zhang, Jian
    Liu, Liming
    Gao, Jie
    Shi, Rong
    Liu, Shengxue
    Wei, Gu
    Qiu, Yang
    Moore, Kathleen
    CANCER RESEARCH, 2023, 83 (08)
  • [2] A FIRST-IN-HUMAN, MULTICENTER, PHASE 1/2, OPEN-LABEL STUDY OF XTX101 IN PATIENTS WITH ADVANCED SOLID TUMORS
    Powderly, John
    Norman, Teleen
    Duncan, Meghan
    Huber, Martin
    O'Neil, Jennifer
    Patel, Ekta
    Vandross, Andrae
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A549 - A549
  • [3] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Beecroft, Claire
    Gao, Bo
    Park, John
    Wilkinson, Kate
    Zhang, Karl
    Yan, Xiangyun
    Lv, Yuan
    CANCER RESEARCH, 2024, 84 (07)
  • [4] Safety and efficacy of JS']JSKN003 in patients with advanced/metastatic solid tumors: A first-in-human, dose-escalation, multicenter, open-label, phase I study
    Park, John J.
    Gao, Bo
    Beecroft, Claire
    Wilkinson, Kate Jessica
    Parsonson, Andrew
    Zhang, Karl
    Yan, Xiangyun
    Wang, Ni
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] A first-in-human, open-label, multicenter phase 1/2a study to evaluate the safety and efficacy of increased repeated doses of the first in class RORγ agonist LYC-55716 in treating locally advanced or metastatic solid tumors
    Wilkins, H. J.
    Hamilton, E. P.
    Mahalingam, D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors
    Ahnert, Jordi Rodon
    Spigel, David R.
    Kremer, Jill
    Jin, Leah
    Benhadji, Karim Adnane
    Gil, Maciej
    Besse, Benjamin
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [7] A phase 1/2a, multicenter, open-label, first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1311 (a B7-H3-targeting ADC) in patients with advanced/metastatic solid tumors
    Cheng, Ying
    Lisberg, Aaron
    Lemech, Charlotte
    Abed, Afaf
    Chaudhry, Arvind
    Schmidt, Andrew
    Lu, Xin
    Zhu, Zhongyuan
    Gu, Wei
    Qiu, Yang
    Shi, Rong
    Zhang, Bin
    CANCER RESEARCH, 2024, 84 (07)
  • [8] A phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1310 (a HER3-targeting ADC) in patients with advanced/metastatic solid tumors
    Lisberg, Aaron
    Lu, Shun
    Starodub, Alexander
    Amin, Harshad
    Rotow, Julia
    Wu, Lin
    Spira, Alexander
    Hamilton, Erika
    Shen, Weidi
    Liu, Liming
    Zhu, Zhongyuan
    Gu, Wei
    Qiu, Yang
    Shi, Rong
    Liu, Shengxue
    CANCER RESEARCH, 2024, 84 (07)
  • [9] An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors
    Rodon, J.
    Li, J.
    Xue, J.
    Diao, Y.
    Xu, Y.
    Liu, G.
    Rao, C.
    Fan, B.
    Cheng, Y.
    Wang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S585 - S585
  • [10] A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors.
    Boni, Valentina
    Garralda, Elena
    Colombo, Ilaria
    Homicsko, Krisztian
    Brana, Irene
    Gruber, Dorothea
    Fluckiger-Mangual, Stefanie
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345